Figure 3.

Silencing FUNDC1 enhances cervical cancer cells chemosensitivity to cisplatin and radiosensitivity in vitro. (A) FUNDC1 knockdown enhanced Hela229 and CaSKi cells sensitivity to cisplatin. Cells were treated with cisplatin for 24 h at the indicated concentration. The cell viabilities were detected by MTT assay. (B) Silencing of FUNDC1 enhanced radiosensitivity in Hela229 (left) and CaSKi (right) cells. The responses of cells to IR at indicated dose were examined by clonogenic survival assays. All data represent the mean ± SE derived from three individual experiments with triplicate wells. (*P < 0.05, **P < 0.01, Student's t‐test)